• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
 
Generic Name:  Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1
Trade Name:  N/A
Date Designated:  10/13/2009
Orphan Designation:  Treatment of glioblastoma multiforme
Orphan Designation Status:  Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Marketing Approval Date:  N/A
Approved Labeled Indication:  
Exclusivity End Date:    N/A
Apogenix GmbH
Im Meuenheimer Feld 584
Germany

The sponsor address listed is the last reported by the sponsor to OOPD.
-
-